Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors
NCT05415475
Colonic Diseases, Colorectal Cancer
Jinan, Shandong, China
View Trial DetailsNCT Number: NCT01589900
Sox2 has been studied in several types of human solid tumors. The investigators found that Sox2 had higher expression level in colorectal cancer and metastatic tissues than normal tissues. So the investigators assumed that whether Sox2 plays an important role in the progression and migration of colon cancer.
Looking for future studies?
Notify Me24 year–79 year
All sexes
Observational
In our study, we examined Sox2 expression in archived human colon cancer tissues and found that its Sox2 expression correlates with reduced patient survival, increased tumor grade and metastasis probability.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Sun Yat-sen University
Other
The Role of Sox2 in Tumor Genesis and Migration in Colorectal Cancer
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05415475
Colonic Diseases, Colorectal Cancer
Jinan, Shandong, China
View Trial DetailsNCT07650786
Colonic Diseases, Colorectal Cancer
Harbin, China
View Trial DetailsNCT06884839
Colonic Diseases, Colorectal Cancer
Minya, Minya Governorate, Egypt
View Trial DetailsNCT04776837
Biliary Tract Cancer, Biliary Tract Diseases
Boston, Massachusetts, United States
View Trial Details